MaxCyte (MXCT) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

MXCT MaxCyte

Watchlist

4.240
+0.100+2.42%

Close Dec 20 16:00 ET

4.240
0.0000.00%

Post 20:01 ET

447.25MMarket Cap-12.47P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

BlackRock Adjusts Stake in MaxCyte, Influencing Voting Rights
TipRanksDec 18 10:42 ET
MaxCyte Announces Change in Major Shareholdings
TipRanksDec 10 12:18 ET
MaxCyte's Strategic Growth and Cost Efficiency Drive Buy Rating
TipRanksDec 9 11:25 ET
Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating
Moomoo NewsDec 9 09:31 ET · Ratings
MaxCyte (MXCT) Initiated With a Buy at Craig-Hallum
TipRanksDec 9 09:00 ET · Ratings
MaxCyte Completes Operational Review, Adjusts Workforce, and Raises 2024 Revenue Guidance
Quiver QuantitativeDec 9 02:10 ET

Comments

Jaguar8

Sep 16 01:01

NEWS

$MaxCyte (MXCT.US)$
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
MaxCyte (Nasdaq: MXCT; LSE: MXCT) and Kamau Therapeutics have entered a strategic platform license agreement. Kamau gains non-exclusive rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform for research, clinical, and commercial purposes. In return, MaxCyte will receive annual licensing fees and program-related revenu...

Jaguar8

May 22 08:41

$MaxCyte (MXCT.US)$
NEWS
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
MaxCyte has signed a strategic platform license agreement with Legend Biotech to accelerate the discovery and development of cell therapies. Under this non-exclusive worldwide license, Legend Biotech will use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for various cell types, including T cells and NK cells. MaxCyte will receive an...

frogoracletrading

May 8 21:54

$MXCT Support / Resistance Levels

Here are the levels to watch after the sharp move up.
Larger Image: tradingview.com...
$MaxCyte (MXCT.US)$

Moomoo Breakfast US

Apr 13, 2022 07:38

Columns Today's pre-market stock movers: DAL, JPM, NSTG, ATRS and more

Gainers:
• $Antares Pharma (ATRS.US)$ +48.7% (to be acquired by Halozyme (HALO) for $5.60 per share)
• $Sierra Oncology (SRRA.US)$ +37.9% (acquired by GSK for $55 per share)
• $Amryt Pharma (AMYT.US)$ +11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients)
• $BriaCell Therapeutics (BCTX.US)$ +6% (presents development details of...